about
A role for the melanocortin 4 receptor in sexual function.An analgesia circuit activated by cannabinoidsImpaired nociception and pain sensation in mice lacking the capsaicin receptorIdentification and characterization of novel mammalian neuropeptide FF-like peptides that attenuate morphine-induced antinociceptionReversal of neuropathic pain by alpha-hydroxyphenylamide: a novel sodium channel antagonist.Contribution of the tetrodotoxin-resistant voltage-gated sodium channel NaV1.9 to sensory transmission and nociceptive behavior.Activation of melanocortin MC(4) receptors increases erectile activity in rats ex copula.Sodium channel blockade may contribute to the analgesic efficacy of antidepressants.Relative contributions of norepinephrine and serotonin transporters to antinociceptive synergy between monoamine reuptake inhibitors and morphine in the rat formalin model.Melanocortin receptors and erectile function.Fasting enhances the response of arcuate neuropeptide Y-glucose-inhibited neurons to decreased extracellular glucosePreclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor.Block of peripheral nerve sodium channels selectively inhibits features of neuropathic pain in rats.Influence of ligand binding kinetics on functional inhibition of human recombinant serotonin and norepinephrine transporters.Discovery of isoxazole voltage gated sodium channel blockers for treatment of chronic pain.A disubstituted succinamide is a potent sodium channel blocker with efficacy in a rat pain model.Differential effects of neurotoxic destruction of descending noradrenergic pathways on acute and persistent nociceptive processing.Inflammation-induced up-regulation of protein kinase Cgamma immunoreactivity in rat spinal cord correlates with enhanced nociceptive processing.Spinal cannabinoids are anti-allodynic in rats with persistent inflammation.The voltage-gated sodium channel Nav1.9 is required for inflammation-based urinary bladder dysfunction.A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.Discovery of a novel class of biphenyl pyrazole sodium channel blockers for treatment of neuropathic pain.Discovery of potent, selective, and orally bioavailable 3H-spiro[isobenzofuran-1,4'-piperidine] based melanocortin subtype-4 receptor agonists.Optimization of privileged structures for selective and potent melanocortin subtype-4 receptor ligands.Discovery of novel 6,6-heterocycles as transient receptor potential vanilloid (TRPV1) antagonists.Discovery of a novel class of isoxazoline voltage gated sodium channel blockers.The 5-HT3 subtype of serotonin receptor contributes to nociceptive processing via a novel subset of myelinated and unmyelinated nociceptors.Design and pharmacology of N-[(3R)-1,2,3,4-tetrahydroisoquinolinium- 3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)- 2-[4-cyclohexyl-4-(1H-1,2,4-triazol- 1-ylmethyl)piperidin-1-yl]-2-oxoethylamine (1), a potent, selective, melanocortin subtype-4 receptor agoThe rodent amygdala contributes to the production of cannabinoid-induced antinociception.Discovery of (2S)-N-[(1R)-2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-4-methyl-2-piperazinecarboxamide (MB243), a potent and selective melanocortin subtype-4 receptor agonist.Varicella zoster virus induces neuropathic changes in rat dorsal root ganglia and behavioral reflex sensitisation that is attenuated by gabapentin or sodium channel blocking drugs.In vivo pharmacological characterization of TD-4208, a novel lung-selective inhaled muscarinic antagonist with sustained bronchoprotective effect in experimental animal models.Application of the classical Einthoven model of bronchoconstriction to the study of inhaled bronchodilators in rodents.Pharmacologic characterization of GSK-961081 (TD-5959), a first-in-class inhaled bifunctional bronchodilator possessing muscarinic receptor antagonist and β2-adrenoceptor agonist properties.Novel cyclopentane dicarboxamide sodium channel blockers as a potential treatment for chronic pain.1-Amino-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid as a Tic mimetic: application in the synthesis of potent human melanocortin-4 receptor selective agonists.Discovery and activity of (1R,4S,6R)-N-[(1R)-2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-2-methyl-2-azabicyclo[2.2.2]octane-6-carboxamide (3, RY764), a potent and selective melanocortiRelationship between sodium channel NaV1.3 expression and neuropathic pain behavior in rats.Synthesis and SAR of 1,2-trans-(1-hydroxy-3-phenylprop-1-yl)cyclopentane carboxamide derivatives, a new class of sodium channel blockers.Currying favor with central inhibitory circuits. Focus on: "effects of TRPA1 agonists mustard oil and cinnamaldehyde on lumbar wide-dynamic range neuronal responses to innocuous and noxious cutaneous stimuli in rats".
P50
Q24535020-D8C32F4F-DF3B-4693-9C70-50CA8B718F6CQ28284331-4927F727-59E5-453E-BA52-B190E9F92130Q28511370-BFF8060F-8BDF-499A-882A-B21CCA3D485EQ28577654-AFBD4903-5FD0-4521-B4AB-BB2D32E5D37EQ30439460-2BDB8CF4-4478-45A4-A187-C0B1B30B0F2EQ33878908-D3A0D3C2-74DD-42A4-8CFE-C87F765C738DQ34157024-6FB9F51A-5A67-4EE3-BD96-6C10BF6A098AQ34592159-9D303851-DFDE-467B-AFB9-B096E408C8D3Q35009932-0C51F13E-DA04-4693-AE70-27BD3222E1AFQ35776539-1C0AB203-C0B2-4E9B-9070-03B656B5952DQ37162412-C2D46181-506B-4F56-8702-C0753D1DFBD6Q39072339-B3DE0F82-F3B4-488C-BCDA-B9F8458AB146Q39358962-0E90C304-841E-42C5-B0F3-6FEE8C65C09AQ39758568-BD0730FE-E64E-4D96-A845-0713D6AA83BEQ39812264-75EF727F-2D81-452A-B2F4-0FF6A6D0B7E9Q40531533-4BF8F1A9-E2EF-4D78-957B-D28654547917Q41646255-AD26B7B5-4635-4A74-923C-80AE3E6F1612Q41666416-2943E83E-3B53-41BC-9461-6DF2D588681CQ41687745-B8069C65-E02A-479C-86A1-DBD8F08DC196Q42447844-9BA3A9CD-8D13-4E77-84CF-72F57C801FE9Q42713271-F2CF6FBC-91AF-4152-8558-91F722F46EC3Q42792634-E3A9C72E-39EA-4F5B-97C1-8DB614F53AB0Q42973768-2556EACC-3034-4FC2-9290-949CAA41499CQ42991385-57C7DC69-756C-423B-80E8-EEAA46C9284AQ43122245-A9B18265-360B-4463-A81A-2D4A606E42C4Q43292921-07D65465-58F6-4BA9-9247-0A9A32F63354Q43875620-0AA7A5AB-192C-43DB-BF69-489958D18C96Q44165911-D650F8D5-B3CE-4BCB-BED9-DD57D47FC015Q44555016-DB8E71E2-7EF4-4D96-AB05-AA6EC73B549FQ45176043-77E2DE8A-73CD-4289-A059-0DB9F9F85F59Q45423431-9BB1383B-F491-446F-8105-52E03DAD9076Q45967968-03BD1DEB-AC2E-4612-B34F-CD5C76C5C18CQ46172742-95A4A01A-EB89-4AFA-A47F-3C82C9654B8EQ46264222-80241DEE-AE15-40C4-9F21-A5790EDE661DQ46394249-3DDA4BB0-A324-48CE-95BE-C9AC9AE79876Q46541814-CB200AF1-4CED-45FC-8C7F-74FD3B17FDD8Q46570240-4948122D-7477-4175-9036-820E695F9463Q46629853-C08CDF92-32E9-4BCF-9E34-45E51FD8AC69Q46842090-E9875349-A928-4306-91CF-EBF653557AC4Q46918451-F3DE4344-EAF4-4577-863A-11DA77EF93BA
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
William J. Martin
@ast
William J. Martin
@en
William J. Martin
@es
William J. Martin
@nl
William J. Martin
@sl
type
label
William J. Martin
@ast
William J. Martin
@en
William J. Martin
@es
William J. Martin
@nl
William J. Martin
@sl
prefLabel
William J. Martin
@ast
William J. Martin
@en
William J. Martin
@es
William J. Martin
@nl
William J. Martin
@sl
P1053
L-9033-2017
P106
P1153
35079188200
P21
P31
P3829
P496
0000-0002-2749-3365